Public Employees Retirement System of Ohio Takes $77,000 Position in Kamada Ltd. (NASDAQ:KMDA)

Public Employees Retirement System of Ohio acquired a new position in shares of Kamada Ltd. (NASDAQ:KMDAFree Report) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 14,270 shares of the biotechnology company’s stock, valued at approximately $77,000.

Separately, Plato Investment Management Ltd bought a new stake in shares of Kamada during the 3rd quarter valued at approximately $117,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Stock Performance

Shares of NASDAQ:KMDA opened at $5.90 on Monday. The company has a market capitalization of $339.13 million, a P/E ratio of 21.07 and a beta of 0.99. Kamada Ltd. has a fifty-two week low of $4.74 and a fifty-two week high of $6.53. The company’s 50-day moving average is $5.78 and its 200 day moving average is $5.55.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. StockNews.com downgraded Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, November 14th.

Check Out Our Latest Research Report on KMDA

Kamada Company Profile

(Free Report)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Featured Articles

Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDAFree Report).

Institutional Ownership by Quarter for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.